THE BIOMARKER
DISCOVERY COMPANY
CiberMed is a stealth biotechnology company started by industry veterans and Stanford University professors.
Our mission is to be the industry leader in the discovery and measurement of biomarkers using our patented technology which uses novel in silico cell sorting to determine cell proportions and gene expression.
Technologies
Biomarker Discovery
CiberMed applies a variety of data science techniques including machine learning that lead to biomarker discovery. The CiberMed data science team develops biomarker models using immune cell data quantified by iSort™
iSort™
iSort™ is a digital cytometry. It quantifies immune cell subsets in silico using gene expression data. The core technology is based on CIBERSORT and CIBERSORTx platforms, that were originally developed at Stanford University, and licensed to CiberMed.
Advantages of iSort™
iSort™ digital cytometry provides highly accurate and robust cell subset enumeration from clinical biospecimens.
Cost-effective and high-throughput
Highly reproducible
Unaffected by tissue dissociation
Applicable to fresh, frozen, and fixed tissues
Applicable to pre-existing gene expression data
Products and Services
| iSort™ | |||||
|---|---|---|---|---|---|
|
Map & Quant |
iSort™ Fractions Quantifies immune cells |
iSort™ Hires Infers cell-type-specific gene expression |
Create custom signature matrix | Biomarker discovery
Post data analysis |
|
| Collaboration | ✓ | ✓ | ✓ | ✓ | ✓ |
| Run iSort™ (Self-service) |
✓ | ✓ | ✓ | ||
- Collaboration User to select the type(s) of services. Consultations included.
- Run iSort™ User to download and run iSort™ module(s)
Click HERE to know more about our products and services including pricing.
Still cannot find the information you are looking for? Contact us.
BIOINFORMATICS / DATA SCIENCE
Our team consists of talented and experienced bioinformatics / data scientists from industry and academia (Stanford Medicine).
Publications
About iSort™ Technology
Analytical validation of digital cytometry (iSortTM) for leukocyte enumeration using stored blood
Newman, A.M., Nakao, A. et.al. J. Clinical Oncology, 38, 15, Supp. 3452 (2020) (Presented at ASCO)
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3542
Analytical validation of iSort™ digital cytometry for leukocyte enumeration in clinical tumor specimens
Newman, A.M., Nakao, A, et.al. J. Clinical Oncology, 38, 15, Supp. e15243 (2020)
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e15243
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A.M. et al. Nature Biotechnology 37, 773–782 (2019)
https://pubmed.ncbi.nlm.nih.gov/31061481/
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. et al. Nature Medicine 21, 938-945 (2015)
https://pubmed.ncbi.nlm.nih.gov/26193342/
Robust enumeration of cell subsets from tissue expression profiles
Newman, A.M. et al. Nature Methods 12, 453–457 (2015)
https://pubmed.ncbi.nlm.nih.gov/25822800/
iSort™ applications
Molecular and immunological signatures are related to clinical benefit from treatment with Vocimagene amiretrorepvec (Toca 511) and 5-fluorocytosine (Toca FC) in patients with glioma
Accomando, W.P. et.al. Clinical Cancer Research (2020)
https://clincancerres.aacrjournals.org/content/early/2020/10/21/1078-0432.CCR-20-0536
iSort™ is based on CIBERSORTx technology. Explore more applications.
